The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Drug discovery and development: Role of basic biological research
Open accessAbstract
This article provides a brief overview of the processes of drug discovery and development. Our aim is to help scientists whose research may be relevant to drug discovery and/or development to frame their research report in a way that appropriately places their findings within the drug discovery and development process and thereby support effective translation of preclinical research to humans. One overall theme of our article is that the process is sufficiently long, complex, and expensive so that many biological targets must be considered for every new medicine eventually approved for clinical use and new research tools may be needed to investigate each new target. Studies that contribute to solving any of the many scientific and operational issues involved in the development process can improve the efficiency of the process. An awareness of these issues allows the early implementation of measures to increase the opportunity for success. As editors of the journal, we encourage submission of research reports that provide data relevant to the issues presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
The Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Target-based drug discovery: is something wrong?
Sams-Dodd, F. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03316-1 · Cited by 522
Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
Hwang, T. J., Carpenter, D., Lauffenburger, J. C., Wang, B., Franklin, J. M., & Kesselheim, A. S. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6008 · Cited by 442
Mustapic, M., Eitan, E., Werner, J. K., Berkowitz, S. T., Lazaropoulos, M. P., Tran, J., Goetzl, E. J., & Kapogiannis, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00278 · Cited by 441
Science Business: The Promise, the Reality and the Future of Biotech
Li, W. (2007) · Journal of Commercial Biotechnology · doi:10.1057/palgrave.jcb.3050059 · Cited by 409
Positron emission tomography molecular imaging for drug development
Matthews, P. M., Rabiner, E. A., Passchier, J., & Gunn, R. N. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04085.x · Cited by 320
Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease
Kozauer, N., & Katz, R. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1302513 · Cited by 193
Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility
Mortamais, M., Ash, J. A., Harrison, J., Kaye, J., Kramer, J., Randolph, C., Pose, C., Albala, B., Ropacki, M., Ritchie, C. W., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.2365 · Cited by 190
Preparing for Responsible Sharing of Clinical Trial Data
Mello, M. M., Francer, J. K., Wilenzick, M., Teden, P., Bierer, B. E., & Barnes, M. (2013) · New England Journal of Medicine · doi:10.1056/nejmhle1309073 · Cited by 175
Becker, R. E., Greig, N. H., & Giacobini, E. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15213 · Cited by 158
Self-citationA decade of innovation in pharmaceutical R&D: the Chorus model
Owens, P. K., Raddad, E., Miller, J. W., Stille, J. R., Olovich, K. G., Smith, N. V., Jones, R. S., & Scherer, J. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4497 · Cited by 83
Medicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs
Choi, D. W., Armitage, R., Brady, L. S., Coetzee, T., Fisher, W. W., Hyman, S. E., Pande, A. C., Paul, S. M., Potter, W. Z., Roin, B. N., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.027 · Cited by 77
Lost in Translation: Neuropsychiatric Drug Development
Becker, R. E., & Greig, N. H. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000446 · Cited by 59
Self-citationShaffer, C. L. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45004-6 · Cited by 53
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
Doody, R. S., Raman, R., Sperling, R. A., Seimers, E., Sethuraman, G., Mohs, R. C., Farlow, M. R., Iwatsubo, T., Vellas, B. J., Sun, X., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0121-6 · Cited by 46
Self-citationKaitin, K. I., & Milne, C. (2011) · Scientific American · doi:10.1038/scientificamerican0811-16 · Cited by 44
Becker, R. E., Seeman, M. V., Greig, N. H., & Lahiri, D. K. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00214-x · Cited by 16
Self-citation
Cited by
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“The current drug discovery challenges are related to the toxicity of the drug, its side effects, choosing the right target site, appropriate dosages, and even intellectual property [447].”
BackgroundPlant-Derived Natural Products: A Source for Drug Discovery and Development
Chaachouay, N., & Zidane, L. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3010011 · Cited by 1,081
Artificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018
Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 390
Metadata
- Authors
- Mohs, R. C., & Greig, N. H.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2017-11
- Volume
- 3
- Issue
- 4
- Pages
- 651-657
- ISSN
- 2352-8737 (ISSN-L)
- OpenAlex
- W2767711842
- Cited by
- 673
- References
- 28
- FWCI
- 25.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.